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EVALUATION OF IRON STATUS IN RENAL FAILURE PATIENTS
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Hypochromic red blood cells and reticulocytes. The manage- full-blown hypochromic, microcytic anemia had devel-
ment of recombinant human erythropoietin (rHuEPO) treat- oped. Given the red cell lifespan of 120 days, it generally
ment in hemodialysis patients requires close monitoring of iron takes several months before this condition evolves.status, because the pharmacologically stimulated erythropoie-
In functional iron deficiency, iron-deficient erythro-sis is particularly dependent on a continuous supply of iron.
poiesis occurs in iron-replete individuals. Such patientsParameters commonly measured to assess iron status are serum
ferritin and the transferrin saturation. Both are indirect mea- display a normal or even elevated serum ferritin, whereas
sures of iron availability for hemoglobin synthesis and fre- the transferrin saturation is low (less than 20%). Thus,
quently do not permit an assessment of the adequacy of iron many centers are using this parameter to get a handlesupply to the erythron. Using flow cytometry, cell volume and
on iron supply to the bone marrow. However, transferrinhemoglobin concentration can be measured in individual red
saturation is a highly labile parameter that may changeblood cells and reticulocytes. Based on these techniques, two
parameters have proved to be particularly useful in identifying greatly during the period of only a few days, thereby
iron-deficient erythropoiesis. (a) The percentage of hypochro- limiting its usefulness in the clinical setting. More re-
mic erythrocytes (defined as red blood cells with a hemoglobin
cently, parameters have become available that allow aconcentration of less than 28 g/dl) has been shown to detect
more direct estimate of bone marrow iron supply. Byinsufficient marrow iron supply with a fairly good accuracy.
(b) More recently, determination of the content of hemoglobin measuring the percentage of red blood cells and/or by
in reticulocytes (CHr) has been suggested by a number of quantitating reticulocyte hemoglobin content, it is possi-
authors to be even more sensitive in detecting iron-deficient ble to gain direct insight into the adequacy of marrowerythropoiesis. For those who have access to an H*3 hematol-
iron supply. In this article, we review the current useogy analyzer, both indices can be determined at the time of a
of red cell hypochromia as a diagnostic index of iron-routine blood count at a minimal incremental cost.
deficient erythropoiesis, discuss some of the problems
inherent in using this parameter, and end with addressing
Patients treated by recombinant human erythropoietin the measurement of reticulocyte hemoglobin content as
(rHuEPO) may require large amounts of iron to meet a new diagnostic approach to quantitate iron supply to
the enhanced iron demand of the bone marrow during the bone marrow.
pharmacologically stimulated erythropoiesis. If adequate
iron supply is not maintained in a timely and quantitative
MEASUREMENTS OF RED CELL INDICESmanner, the hematological response to rHuEPO will be
Based on work by Wintrobe in the early 1930s [2, 3],impaired, and an expensive therapy will come to naught.
MCV and MCHC were established as indices to charac-In fact, iron-deficient erythropoiesis has been reported
terize red blood cells in patients with anemia. Originally,to be the most frequent cause of hyporesponsiveness to
these indices were derived from manually measured val-rHuEPO [1] and may even occur in the presence of
ues of hemoglobin, red cell count, and hematocrit. Theseperfectly adequate iron stores. This condition is called
“functional iron deficiency,” and its early detection is of insightful observations have withstood the test of time
the essence because it can be easily treated with i.v. iron, and are still being used today.
thus preventing costly wastage of rHuEPO. In the past, More recently, flow cytometric methods have been
iron-deficient erythropoiesis could be detected only after developed to determine red cell volume either by mea-
it had led to gross changes in the red cell population suring changes in electrical resistance (Coulter principle)
as a whole [reduced mean hemoglobin concentration [4] or by measuring the amount of light scattered by
(MCHC) and mean cell volume (MCV)], that is, when individual red cells. Modern hematology analyzers are
capable of simultaneously and independently measuring
both volume and hemoglobin concentration in individualKey words: erythropoiesis, dialysis, ferritin, hemoglobin, reticulocytes,
blood count. sphered red blood cells using monochromatic light at
two different angular intervals [5, 6]. Based on the lon- 1999 by the International Society of Nephrology
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gevity of erythrocytes, the measurement of individual Five of 14 patients who displayed hypochromic cells
in excess of 10% were treated with parenteral iron (ironred cells, rather than determining mean red cell indices
of the whole erythrocyte population, should allow a rapid dextran) for four weeks. In all cases, hypochromia subse-
quently fell to within the normal range with a corre-identification of small subpopulations of, for example,
hypochromic and/or microcytic cells, as they are pro- sponding increment in the hemoglobin concentration.
Thus, the percentage of hypochromic cells also appearsduced by an iron-deficient erythron.
useful in monitoring intravenous iron supplementation
in rHuEPO-treated individuals.
PERCENTAGE OF HYPOCHROMIC
Comparable findings were published by Schaefer and
RED BLOOD CELLS
Schaefer [9]. In a first set of experiments, these authors
Phlebotomy-induced iron deficiency anemia compared 10 iron-overloaded dialysis patients [ferritin,
2396 6 821 ng/ml; transferrin-saturation (T-Sat), 43 6This was actually shown for the first time by Green,
who induced iron-deficiency anemia by repeated phle- 6%] with 10 patients suffering from absolute iron defi-
ciency (ferritin, 52 6 16 ng/ml; T-Sat, 9 6 2%). The dosebotomies in eight normal male subjects [7]. Over a period
of 143 to 279 days, these individuals were phlebotomized of rHuEPO to maintain either group of patients at a
hemoglobin concentration of 10 g/dl was 48 6 9 U/kgdown to a hemoglobin value of 11 g/dl. Initially, 125 ml
of blood was removed twice weekly until a hemoglobin per week for those with iron overload and 167 6 15 U/kg
per week in the group with absolute iron deficiency.concentration of 13.5 g/dl was reached. At that point,
phlebotomy was continued at 125 ml weekly down to There was clear-cut iron-deficient erythropoiesis in pa-
tients with the absolute iron deficiency, displaying 22 611.0 g/dl. The amount of iron removed ranged from 760
to 3166 mg. Throughout the study, blood counts were 5% of hypochromic red blood cells. By contrast, only
1 6 0.5% of erythrocytes were hypochromic in iron-measured on the H*1 instrument (Bayer Diagnostics,
Munich, Germany). It was seen that when the transferrin overloaded dialysis patients. Unfortunately, these find-
ings cannot differentiate whether there was iron-defi-saturation fell below 15%, the earliest change in erythro-
cyte indices was an increase in the percentage of hypo- cient erythropoiesis because iron supply was too low (as
indicated by the T-Sat of 9%) or because of a much morechromic red cells (red cell hemoglobin concentration
below 28 g/dl) rather than any change in volume. This pronounced marrow stimulation (as the dose of rHuEPO
was more than threefold higher in iron-depleted patients).feature was clearly seen in the H*1 measurements but
was not evident in impedance cytometry (Coulter Counter; For these reasons, a second group of 10 rHuEPO-naive
dialysis patients were commenced on rHuEPO with aBeckman Coulter, Inc., Fullerton, CA, USA), which gives
only the MCV. The reason that it takes some time before constant dose of 150 U/kg/week. During the first four
weeks, iron supplementation was withheld, whereas inthe MCV falls below 80 fl is primarily a reflection of the
longevity of erythrocytes. the second four-week interval, a total of 750 mg of iron
gluconate was given intravenously. Prior to rHuEPO,
rHuEPO-induced functional iron deficiency the hemoglobin was 8.5 6 1.2 g/dl. The T-Sat was 17 6
3%, and the percentage of hypochromic red cells wasPharmacologic stimulation of the bone marrow by
rHuEPO may cause iron-deficient erythropoiesis, which, normal (less than 2.5%). Four weeks of rHuEPO treat-
ment caused hemoglobin concentration to increase toin the presence of adequate iron stores, has been termed
“functional iron deficiency.” In the past, this condition 10.5 g/dl and T-Sat to decline to 12 6 1%. As expected,
the percentage of hypochromic erythrocytes rose consid-was assumed when the transferrin saturation was low.
This had considerable limitations because the saturation erably (15.3 6 1.5%). These data show two important
aspects. First, in uremia, red cell hypochromia may bevaries substantially even in normal, healthy subjects. By
using the H*1 Technicon blood count analyzer, MacDou- absent despite low transferrin saturations in patients not
treated by rHuEPO, due to low-turnover erythropoiesis.gall et al [8] followed the percentage of hypochromic
red cells in 46 rHuEPO-treated dialysis patients during Second, when rHuEPO is started in such patients,
marked hypochromia may develop within a few weeks.the correction phase of their anemia. The proportion of
hypochromic cells progressively increased with rHuEPO In the second four-week period, intravenous iron was
given in addition to rHuEPO. This led to a further in-treatment. This was paralleled by a fall in the transferrin
saturation, in some instances even preceding it. On the crease in the hemoglobin concentration (12.0 g/dl). The
transferrin saturation rose to 20 6 2%, and hypochromicother hand, mean red cell parameters [MCV, mean cor-
puscular hemoglobin (MCH), and MCHC] remained un- red cells declined to 5.5 6 0.8% after four weeks of iron
therapy. Thus, red cell hypochromia may not only bechanged over the 12-week study period, indicating that
changes in the whole red cell population are too slow to used to detect iron-deficient erythropoiesis, but may also
be employed to monitor iron supplementation.be useful in measuring iron supply to the marrow during
rHuEPO therapy. These observations were corroborated by Braun et al
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[10], who studied the iron status in 70 hemodialysis pa- rHuEPO, even though transferrin saturation and ferritin
levels fell over the course of the donation period.tients with or without rHuEPO therapy. The authors
found that hypochromic red cells above 6% were reliable By using very high doses of rHuEPO (200 U/kg per
day), the authors could clearly demonstrate that the limi-predictors for the dose of rHuEPO to fall once parenteral
iron therapy was started. Moreover, the majority of pa- tations of iron availability became apparent long before
iron stores were depleted. On the other hand, iron over-tients without rHuEPO had hypochromic red cells below
6%. Interestingly, the authors identified a small subpop- load, as observed in the patient with hemochromatosis,
did prevent the development of iron-deficient erythro-ulation of dialysis patients with more than 6% of hypo-
chromic red cells who were not treated with rHuEPO, poiesis and led to a much greater amount of red blood
cells that could be donated. This observation providesbut who did respond to intravenous iron by increasing
their hemoglobin concentrations. This observation sug- evidence that insufficient iron availability not only causes
red cell hypochromia, but that the whole hematologicgests that by measuring red cell hypochromia, it may be
possible to identify dialysis patients who may correct response to rHuEPO will be quantitatively diminished.
their anemia with iron therapy alone.
Braun et al also had the opportunity to study the
RETICULOCYTE HEMOGLOBIN CONTENT
hematologic response to parenteral iron in a small group
With the advent of the H*3 hematology analyzerof C-reactive protein (CRP)-positive patients on rHuEPO
(Bayer Diagnostics), it became possible to identify both[10]. Patients with hypochromic red cells above 6% bene-
red blood cells and reticulocytes within the same bloodfited significantly from intravenous iron, whereas those
sample. The H*3 red blood cell counting method is iden-with hypochromic cells below 6% did not increase their
tical to that of the previous H*1 and H*2 systems [5, 6],hemoglobin concentration after iron therapy.
whereas reticulocytes can be counted with greatly im-Fishbane et al reported on the sensitivity and specific-
proved precision and accuracy based on measurementsity of various parameters used to detect iron-deficient
of fluorescence after staining with RNA-binding fluoro-erythropoiesis [11]. Patients were defined as iron-deficient
chromes (Oxazine 750) [13]. Moreover, from the amountwhen they responded to a single intravenous dose of 1000
of light scattered at two different angles, the H*3 ana-mg of iron dextran by a sustained reticulocyte increase of
lyzer can also measure reticulocyte mean corpuscular1%. In the hands of these authors, hypochromia in more
volume (MCVr in fl) and corpuscular hemoglobin con-than 10% of red cells was found to have a surprisingly
centration mean (CHCMr in g/dl). The mean hemoglo-low sensitivity of 42.8% (N 5 7 patients) and a specificity
bin content of reticulocytes (CHr in pg) is subsequentlyof 80% (N 5 25 patients) to detect iron-deficient erythro-
calculated from the product of volume times hemoglobinpoiesis, which was less than the sensitivity of ferritin (less
concentration of individual reticulocytes [14].than 100 mg/liter) or of the transferrin saturation (less
Brugnara et al were the first to evaluate reticulocytethan 20%). The most likely explanation might be that
properties using the H*3 system in healthy volunteersthe number of patients (N 5 7) was insufficient to allow
being treated with rHuEPO [15]. Twenty-four individu-for a meaningful calculation of the sensitivity. It may
als were treated subcutaneously with three differentalso be that hypochromia in more than 10% of red cells
rHuEPO protocols (group I, 300 U/kg on days 1, 4, 7, andis too high of a cut-off point and that 5% would be more
10; group II, 400 U/kg on days 1, 5, and 9; group III, 600appropriate.
U/kg on days 1 and 10). All subjects received oral ironBrugnara et al studied the effect of subcutaneous
(300 mg/day). Administration of rHuEPO was associatedrHuEPO on red blood cell regeneration for autologous
with a significant increase in the production of reticulo-donation in six iron-replete subjects with normal renal
cytes. The CHr was approximately 28 pg in the threefunction [12]. Iron was supplemented orally as ferrous
groups studied prior to rHuEPO treatment. At day 10 ofsulfate. Subcutaneous rHuEPO caused a marked reticu-
rHuEPO administration, the CHr had declined to 24.6 pglocytosis (568,000 6 159,000/ml vs. 235,000 6 77,000/ml)
in group I and 24.5 pg in group II and returned to baselineand enhanced red cell production at 28 days (1208 6
within two weeks after rHuEPO was discontinued. When227 ml vs. 719 6 161 ml). In addition, one subject with
the percentage of reticulocytes with a CHr of less thanhemochromatosis was also followed. This individual pro-
23 pg of hemoglobin per cell was calculated, the followingduced substantially more red cells (1764 ml at day 28).
picture emerged: At baseline, 5.6%, 6.9%, and 8.3% ofNormal subjects treated with rHuEPO (but not the
reticulocytes were hypochromic in groups I, II and III,rHuEPO-treated individual suffering from hemochro-
respectively. At day 10 of rHuEPO treatment, the per-matosis) started to produce hypochromic red blood cells
centage of hypochromic reticulocytes had reached 39%between days 8 and 16 of the trial in advance of any
in group I and 40% in group II. As the production oflaboratory evidence of depleted iron stores. On the other
hypochromic reticulocytes was inversely correlated withhand, no functional iron deficiency was observed when
the same subjects donated blood in the absence of the baseline serum ferritin and was associated with a
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marked decrease of the transferrin saturation, the au- two percent of patients who displayed reticulocytosis
had an increment in their CHr values by more than 2thors concluded that the evolution of reticulocyte hypo-
chromia is proof of iron-deficient erythropoiesis. pg. CHr rose within 48 hours, peaked at 96 hours, and
then fell back toward baseline. A CHr of less than 28The reticulocyte hemoglobin content (CHr) was also
used to monitor iron supplementation [16]. Ten female pg predicted functional iron deficiency more accurately
than ferritin or transferrin saturation.patients with absolute iron deficiency anemia were fol-
lowed during oral iron therapy (650 mg of ferrous gluco- Bhandari et al used CHr measurements to monitor
intravenous iron therapy in a prospective nonblindednate per 24 hr). The number of reticulocytes increased
from 65,150 per ml to 130,450 per ml, and the CHr rose study on 22 hemodialysis patients being treated by
rHuEPO [19]. Before intravenous iron supplementation,from 18.1 pg to 23.4 pg. These changes were observed
as early as two weeks into iron replacement therapy and serum ferritin was below 60 mg/liter, indicating absolute
iron deficiency. When intravenous iron therapy was initi-long before the hemoglobin started to rise (1 g/dl at day
28). There were two patients who did not respond to ated, there was an increase in the number of reticulocytes
and in CHr values. In this straightforward situation oforal iron replacement. These two females were correctly
identified at day 14 by the persistence of abnormally low absolute iron deficiency, CHr picked up iron-deficient
erythropoiesis with great accuracy and immediately re-CHr values (16 and 18.5 pg, respectively). Only when
intravenous iron dextran was administered did the CHr sponded to iron therapy.
and later the hemoglobin concentrations begin to rise [16].
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